

Candriam Sustainable Equity Emerging Markets

Market Overview

In January, EM posted negative returns (-4.7% in USD) and underperformed DM (+1.1%).

In China (-10.6%), despite an in-line GDP growth (5.2%) for 2023, the overall weak trajectory continued. The ongoing challenges were especially underscored by persistent deflation, contracting manufacturing PMI, and soft credit data. Although the PBoC injected more liquidities and reduced the Reserve Requirement Ratio (RRR) by 50bps, resulting in a brief market rebound, sentiment remained cautious and awaited further restoration.

Taiwan (-1.5%) and South Korea (-9.7%) posted negative returns during the month while Taiwan outperformed. The technology-led exports regained strength helping the economy. The semiconductor industry saw more confirmation of a turning point, and the confidence was additionally boosted by fast growing orders stemming from the accelerated adoption of AI. Taiwan elected a new president from the Democrats, just as his predecessor. This will have a positive impact on the stability of the chip supply chain. Meanwhile, South Korea witnessed its highest exports growth since May 2022. The Korean government mulled new policies to enforce corporate disclosure and narrow the discount of undervalued companies.

Indian market (+2.5%) continued to be strong. The Indian stock market ascended to the fourth largest among its global peers, fueled by domestic investors' progressing passion. The government's forthcoming interim budget in February was expected to prioritize long term objectives while maintaining fiscal discipline, such as more investments in infrastructure and social-driven projects.

In Latam, Brazil (-5.9%) underperformed peers while the easing cycle continued with another cut of 50bps. In Mexico (-1.9%), moderating inflation provided room for rate cuts in the near term.

Turkey (+10.3%) saw another rate hike. Inflation stayed at high levels but was in line with the central bank's assessment. Greece (+5.8%) also recorded positive performance during the month, as the economy resumed growth following a prolonged period of stagnation.

Regarding commodities, oil gained +6.1% amid the present geopolitical volatilities. Gold eased by -1.1%. US yields retreated below 4% by the end of the month.

Portfolio Highlights & Strategy Review

In January, portfolio outperformed the benchmark. Indian names gained across sectors. Many of them led the performance, including Shriram Finance (lending & insurance) in the Financials sector, Bharti Airtel (telecom operator) in the Communication Services sector, and Apollo hospitals (hospital chain) in the Health Care sector. The positive relative performance was also helped by semiconductor / AI thematic names in portfolio, such as TSMC in Information Technology. On the backdrop of consumption recovery, Latam names such as MercadoLibre and Femsa were among the top positive contributors. The portfolio's performance was partially offset by China detraction. Its Health Care sector was dragged by geopolitical concerns over the US biotech market, while the weak consumer sentiment posed pressure on both Consumer Staples and Consumer Discretionary sectors.



MONTHLY FUND COMMENT

January 2024



Regarding its position adjustment, portfolio increased exposure to the Semiconductor / AI thematic and initiated names such as Asustek Computer (Taiwanese hardware manufacturer) and ASMedia (Taiwanese integrated circuit designer). Meanwhile, the portfolio took profits in MediaTek considering as we waited to see more confirmation of a smartphone recovery. We reduced the portfolio's China exposure delisting Alibaba Health, Hong Kong Exchanges & Clearing, and Kanzhun (Chinese job seeking consultant), etc.

Fund Outlook

We are increasingly optimistic on the prospects for EM equities, as a confluence of headwinds that hindered the performance over the past year begin to dissipate. Higher rates in the US and consequently a strengthening dollar have been a key factor weighing on EM equity returns in recent years. A possible shift to tailwinds is favourable for EM returns, including the potential for US interest rates to peak and a transition towards a more accommodative monetary policy environment. Particularly, these tailwinds are expected to be pronounced for EM growth and ESG factors, which are integral to our EM strategies.

Regionally, EM outside China have been demonstrating notable resilience, weathering the weakness associated with China's slowdown. It has been exemplified by their capacity of turning challenges into opportunities, as the global supply chain undergoes a wide reshuffling. The semiconductor industry witnesses more confirming signals of a turnaround, and the upward of the AI trend continues to be robust, helped by global techs' ramping up investments.

China experienced sporadic bounces entering the new year. The subdued sentiment leads to mounting hopes that some transformative support should be seen from the government instead of incremental and rippling small policies. With the Lunar New Year approaching, we are closely monitoring market moves from a tactical perspective.

Aligned with our strategy, we will dynamically calibrate the portfolio's risk appetite in response to evolving market conditions, maintaining a balanced position. We are awaiting further confirmation that the peak of interest rates is behind us, and that China's economic recovery is gaining momentum, thus contributing to the differential growth of EM.

This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change. In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.

Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. Investor rights and complaints procedure, are accessible on Candriam's dedicated regulatory webpages https://www.candriam.com/en/professional/legal-and-disclaimer-candriam/regulatory-information/. This information is available either in English or in local languages for each country where the fund's marketing is approved. According to the applicable laws and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.

Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage https://www.candriam.com/en/professional/market-insights/sfdr/. The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Notice to investors in Switzerland: The information provided herein does not constitute an offer of financial instruments in Switzerland pursuant to the Swiss Financial Services Act ("FinSA") and its implementing ordinance. This is solely an advertisement pursuant to FinSA and its implementing ordinance for financial instruments.

Swiss representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The legal documents as well as the latest annual and semi-annual financial reports, if any, of the investment funds may be obtained free of charge from the Swiss representative.

Swiss paying agent: CAČEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy, 35, CH-1260 Nyon. Place of performance: Route de Signy 35, CH-1260 Nyon. Place of jurisdiction: Route de Signy 35, CH-1260 Nyon.

Specific information for investors in France: the appointed representative and paying agent in France is CACEIS Bank, Luxembourg Branch, sis 1-3, place Valhubert, 75013 Paris, France. The prospectus, the key investor information, the articles of association or as applicable the management rules as well as the annual and semi-annual reports, each in paper form, are made available free of charge at the representative and paying agent in France.

Specific information for investors in Spain: Candriam Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch. CNMV: 1493

